TCRT vs. SPRB, EGRX, AGLE, TPST, DERM, LABP, GNLX, ELDN, BTAI, and AEON
Should you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Spruce Biosciences (SPRB), Eagle Pharmaceuticals (EGRX), Aeglea BioTherapeutics (AGLE), Tempest Therapeutics (TPST), Journey Medical (DERM), Landos Biopharma (LABP), Genelux (GNLX), Eledon Pharmaceuticals (ELDN), BioXcel Therapeutics (BTAI), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.
Alaunos Therapeutics (NASDAQ:TCRT) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.
In the previous week, Spruce Biosciences had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Spruce Biosciences and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.89 beat Spruce Biosciences' score of 0.72 indicating that Alaunos Therapeutics is being referred to more favorably in the media.
Spruce Biosciences received 31 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 63.33% of users gave Spruce Biosciences an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
Alaunos Therapeutics has higher earnings, but lower revenue than Spruce Biosciences.
Spruce Biosciences has a consensus target price of $5.67, suggesting a potential upside of 664.63%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Alaunos Therapeutics.
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 5.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Alaunos Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500.
Alaunos Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -461.67%. Spruce Biosciences' return on equity of -57.53% beat Alaunos Therapeutics' return on equity.
Summary
Spruce Biosciences beats Alaunos Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Alaunos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alaunos Therapeutics Competitors List
Related Companies and Tools
